Mounjaro release date?

See the DrugPatentWatch profile for Mounjaro

When is the Mounjaro release date?

Mounjaro (tirzepatide), an injectable treatment for type 2 diabetes and obesity, was approved by the US FDA on May 13, 2022 [1]. However, a specific release date for Mounjaro can be misleading since its availability has been gradual.

What is the current status of Mounjaro?

Eli Lilly, the manufacturer of Mounjaro, initially announced plans for a summer 2022 launch [2]. Following the FDA approval, Lilly stated that the medication would hit the market within weeks.

Availability and distribution

In the US, Mounjaro became available for prescribing in June 2022 [3]. Distribution has been ongoing, with pharmacies and doctors' offices stocking the medication. However, due to high demand, some patients may experience delays in obtaining Mounjaro.

Pricing and insurance coverage

The wholesale acquisition cost (WAC) for Mounjaro 2.5mg injectable solution was approximately $1,300 per 1-month supply, while the WAC for the 5mg solution was about $1,700 per 1-month supply [4]. Insurance coverage for Mounjaro varies, and patients are advised to check their individual plans.

Patent and competition

As of the initial launch, Mounjaro faces patent protection until 2033, as reported on DrugPatentWatch.com [5]. This protection may affect the development and release of potential biosimilars or generic versions.

Source

1. FDA (2022) FDA Approves Mounjaro (tirzepatide) to Improve Glycemic Control in Adults with Type 2 Diabetes
2. Eli Lilly (2022) Lilly Announces U.S. FDA Approval of Mounjaro (Tirzepatide) Injection, 2.5mg and 5mg
3. Eli Lilly (2022) Mounjaro
4. Healthcare Intelligence (2022) Mounjaro (Tirzepatide) Cost and Coupons
5. DrugPatentWatch.com (2022) Tirzepatide Patent Expiration Date, Approval Date, and more